# Yuichiro Ohe

Source: https://onco.cc/people/ohe-yuichiro/  
OnCo record `ohe-yuichiro` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Thoracic oncologist who leads NCC Hospital in Tokyo and has been a Japanese principal investigator on a generation of lung cancer trials.

## Summary

Yuichiro Ohe is Director of the National Cancer Center Hospital in Tokyo and a thoracic oncologist. He has been a Japanese principal investigator on a generation of lung cancer trials, leading Japanese participation in EGFR, ALK and immunotherapy studies in non-small-cell and small-cell lung cancer. His publications include the FLAURA trial of osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. He directs the hospital while continuing work on lung cancer chemotherapy, targeted therapy and clinical trials.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, National Cancer Center Hospital; thoracic oncology
- Specialisms: Lung cancer; Chemotherapy; Targeted therapy; Clinical trials

## Sources

- National Cancer Center Hospital: https://www.ncc.go.jp/en/ncch/index.html
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Ohe%20Y%5BAuthor%5D%20National%20Cancer%20Center%20lung

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Osimertinib](https://onco.cc/drugs/osimertinib/)
- institutions: [Japanese Society of Medical Oncology](https://onco.cc/institutions/jsmo/), [National Cancer Center Hospital](https://onco.cc/institutions/ncc-japan/)
- key papers: [FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer](https://onco.cc/key-papers/paper-flaura-nejm-2018/)

---
JSON: https://onco.cc/api/v1/entities/ohe-yuichiro.json